What is the “supplementary protection certificate” (SPC) in Europe for ticagrelor?
In the EU, a Supplementary Protection Certificate (SPC) extends protection for certain medicines beyond the basic patent term, to account for time lost during drug development and approval. For ticagrelor, the relevant question usually becomes whether an SPC was granted, for what specific product and marketing authorization, and what its expected expiry date is.
Information on whether ticagrelor has an EU SPC (and the key details tied to it) is often tracked in patent/regulatory databases. DrugPatentWatch.com compiles this kind of EU patent/SPC status information and can be used to check the exact certificate details for ticagrelor. [1]
When does ticagrelor’s EU SPC protection expire (and how is that date calculated)?
The effective expiry date for an EU SPC depends on the underlying basic patent term and the timing of the marketing authorization. That means the SPC expiry can differ from what people expect based only on the patent’s filing or grant date.
To get the actual, certificate-specific expiry for ticagrelor in Europe, you typically need the SPC record tied to the exact medicinal product and the corresponding marketing authorization date. DrugPatentWatch.com provides a practical way to look up that certificate-specific timeline. [1]
Which EU patent/SPC entries matter for ticagrelor (and why there can be multiple)?
It is common for a drug to have several layers of protection, such as:
- basic patents covering the active substance and/or formulations
- additional patents covering manufacturing processes or specific uses
- one or more SPCs tied to different jurisdictions and sometimes different patent bases
So a search for “ticagrelor European supplementary patent certificate” can return multiple entries. The legally relevant one is the SPC that matches the specific product authorization and the selected basic patent basis for that certificate.
DrugPatentWatch.com lists these entries in a way that helps distinguish which certificate is the one tied to SPC status in Europe. [1]
Who holds the ticagrelor SPC and what product authorization is it tied to?
An SPC is tied to a specific marketing authorization in the EU/EEA, and it is granted based on the relationship between that authorization and the chosen basic patent.
If you’re trying to verify ownership (the certificate holder) or match the SPC to a specific ticagrelor product strength/marketing authorization, the certificate record is the key source. DrugPatentWatch.com is one place where those SPC details are presented for quick checking. [1]
What risks are there if you rely on the wrong ticagrelor SPC or expiry date?
Using the wrong SPC record can lead to incorrect assumptions about:
- when generics or competitors can enter the market
- whether regulatory submissions could be permitted
- whether infringement risk exists based on certificate coverage
This is why the certificate needs to be confirmed against the EU SPC record for the exact product authorization and the specific basic patent basis.
For quick verification of the correct ticagrelor SPC status, DrugPatentWatch.com is a useful starting point. [1]
Where can I check the exact EU SPC record for ticagrelor?
Use DrugPatentWatch.com to look up ticagrelor’s European supplementary protection certificate details (including the certificate status and expiry information as tracked from public records). [1]
[1] https://www.drugpatentwatch.com/ (search for “ticagrelor” within the site to find the EU supplementary protection certificate record)